Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population

Epilepsia - Tập 49 Số 12 - Trang 2087-2091 - 2008
Chaichon Locharernkul1, Jakrin Loplumlert1, Chusak Limotai1, Wiwat Korkij1, Tayard Desudchit2, Siraprapa Tongkobpetch2, Oratai Kangwanshiratada3, Nattiya Hirankarn3, Kanya Suphapeetiporn2, Vorasuk Shotelersuk2
1Departments of Medicine
2Pediatrics
3Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Tóm tắt

SummaryPurpose: Previous studies found a strong association between HLA‐B*1502 and carbamazepine (CBZ)‐induced Stevens‐Johnson syndrome (SJS) in Han Chinese, but not in Caucasian populations. Even in Han Chinese, the HLA‐B*1502 was not associated with CBZ‐induced maculopapular eruptions (MPE). This study seeks to identify whether HLA‐B*1502 is associated with CBZ‐ or phenytoin (PHT)‐induced SJS or MPE in a Thai population.Methods: Eighty‐one Thai epileptic patients between 1994 and 2007 from the Chulalongkorn Comprehensive Epilepsy Program were recruited. Thirty‐one subjects had antiepileptic drug (AED)‐induced SJS or MPE (6 CBZ‐SJS, 4 PHT‐SJS, 9 CBZ‐MPE, 12 PHT‐MPE), and 50 were AED‐tolerant controls.Results: For the first time, a strong association between HLA‐B*1502 and PHT‐induced SJS was found (p = 0.005). A strong association was also found between the HLA‐B*1502 and CBZ‐induced SJS (p = 0.0005), making Thai the first non‐Chinese population demonstrating such an association. Some patients, who were HLA‐B*1502 and suffered from CBZ‐induced SJS, could be tolerant to PHT and vice versa. This suggests that HLA‐B*1502 may be a common attribute required for a Thai patient to develop SJS from these two AEDs; other different elements, however, are also needed for each AED. In addition, no association between HLA‐B alleles and CBZ‐ or PHT‐induced MPE was found.Conclusions: CBZ‐ and PHT‐induced SJS, but not MPE, is associated with HLA‐B*1502 allele in Thai population.

Từ khóa


Tài liệu tham khảo

10.2217/14622416.7.6.813

10.1212/01.wnl.0000261917.83337.db

10.1038/428486a

10.1097/01.fpc.0000199500.46842.4a

10.2165/00002018-199921060-00005

10.1038/sj.tpj.6500356

10.1111/j.1528-1167.2007.01022.x

10.1212/01.WNL.0000156354.20227.F0

10.1034/j.1399-0039.2002.590308.x

10.1111/1523-1747.ep12388434

Svensson CK, 2001, Cutaneous drug reactions, Pharmacol Rev, 53, 357